Carbidopa clinical trials
Also written Lodosyn.
Counted the way a researcher would: Carbidopa with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Carbidopa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Carbidopa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 May 1975 · SINEMET · NDA 017555 (FDA, Drugs@FDA; in a combination)
- European Union
- 17 Oct 2003 · Stalevo · EMEA/H/C/000511 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
55 studies that test it; most in 2009 (9)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 9 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 32
Novartis (4) · University of Michigan (3) · AbbVie (3) · AbbVie (prior sponsor, Abbott) (3) · Orion Corporation, Orion Pharma (3) · The University of Texas Health Science Center, Houston (3) · Novartis Pharmaceuticals (3) · Chelsea Therapeutics (2)
Often tested with
Tested in the same studies.
Levodopa (41) · Entacapone (13) · Droxidopa (4) · Carbidopa, levodopa drug combination (3) · Histidine (2) · Opicapone (2) · Buspirone (1) · Dopamine agonists (1)
Related medicines
As reviewed, each with the page that says it.
- One of Dopamine Agents source
Studies
Open first, then newest update. How each study uses Carbidopa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 55
- Dopamine Modulation of Motivation and Motor Function in Major Depression & InflammationRecruitingNot applicableCharite University, Berlin, GermanyNCT05909267Written as L-dopa/Carbidopa
- Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's DiseaseRecruitingPhase 4Second Affiliated Hospital of Soochow UniversityNCT06236230Written as levodopa/carbidopa/entacapone
- Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label ArmCompletedPhase 1/2University of MichiganNCT06587217Written as Carbidopa 25 mg
- Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled ArmCompletedPhase 1/2University of MichiganNCT06219915Written as Carbidopa 25 mg
- Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of CarbidopaCompletedPhase 2Chelsea TherapeuticsNCT00983814Written as Droxidopa+Carbidopa
- Neurobiological Drivers of Mobility Resilience: The Dopaminergic SystemCompletedPhase 1/2University of MichiganNCT04325503Written as carbidopa
- A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy SubjectsCompletedPhase 1Impax Laboratories, LLCNCT06161220Written as Carbidopa capsule
- Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With FibromyalgiaCompletedPhase 2Chelsea TherapeuticsNCT01323374Written as Carbidopa
- A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)CompletedPhase 3AbbVieNCT02549092Written as Levodopa-Carbidopa Intestinal Gel
- Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EESCompletedPhase 1Centre Hospitalier Universitaire VaudoisNCT04052776Written as Levodopa-Carbidopa
- Inflammation-related Alterations in Neurocircuitry: Reversal With LevodopaCompletedPhase 4Emory UniversityNCT02513485Written as Levodopa+carbidopa
- Peripheral Dopamine in Postural Tachycardia SyndromeCompletedPhase 2/3Vanderbilt UniversityNCT00685919Written as Carbidopa
- Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke RehabilitationWithdrawnPhase 4Ross D. Zafonte, MDNCT02346630Written as Levodopa / Carbidopa
- Histaminergic Basis of Fatigue in Multiple SclerosisWithdrawnPhase 2University of MiamiNCT04764383Written as Lodosyn
- A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's DiseaseCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01736176Written as Levodopa-Carbidopa Intestinal Gel
- Dose-finding Pharmacokinetic Study in Healthy MalesCompletedPhase 1Orion Corporation, Orion PharmaNCT03055936Written as Carbidopa
- Remission of ICD by Switching Dopamine Agonist to Levodopa/CarbidopaCompletedPhase 4SandozNCT01683253Written as Levodopa/Carbidopa(200mg/50mg)
- Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachCompletedPhase 1University of MiamiNCT03266965Written as Carbidopa
- Norepinephrine-targeted Therapy for Action Control in Parkinson DiseaseCompletedPhase 4Vanderbilt University Medical CenterNCT03115827Written as Carbidopa
- High and Low Dose Carbidopa Treatment of Parkinson's DiseaseCompletedPhase 2Oregon Health and Science UniversityNCT01399905Written as carbidopa
See all 55 studies that test Carbidopa →
Given beside what is tested · 21 — Carbidopa is usual care or a partner of the new treatment
- [18F]F-DOPA Imaging in Patients With Autonomic FailureRecruitingPhase 1Daniel ClaassenNCT04246437Written as Carbidopa 200mg oral dose
- Fexofenadine as Adjuvant Therapy in Parkinson DiseaseRecruitingPhase 2/3Tanta UniversityNCT06785298Written as Levodopa/carbidopa
- Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's DiseaseCompletedPhase 2Tanta UniversityNCT07001150Written as levodopa-carbidopa
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's DiseaseCompletedPhase 2Tanta UniversityNCT05781711Written as levodopa-carbidopa
- Montelukast in Parkinson DiseaseCompletedPhase 2/3Mostafa BahaaNCT06113640Written as levodopa-carbidopa
- An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease SubjectsCompletedPhase 1/2XenoPort, Inc.NCT00914602Written as Carbidopa Pill
- A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease SubjectsCompletedPhase 2XenoPort, Inc.NCT01171313Written as XP21279 and carbidopa (experimental)
- A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066CompletedPhase 3Impax Laboratories, LLCNCT01130493Written as CLE
- Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)CompletedPhase 1Merck Sharp & Dohme LLCNCT00845000Written as Carbidopa
- Treatment of Supine Hypertension in Autonomic FailureCompletedPhase 1Vanderbilt UniversityNCT00223717Written as carbidopa
- The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT02170376Written as Levodopa/carbidopa
- A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking AdultsCompletedPhase 1Acorda TherapeuticsNCT02633839Written as Carbidopa
- A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With AsthmaCompletedPhase 1Acorda TherapeuticsNCT02633007Written as Carbidopa
- Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's DiseaseCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01479127Written as Oral Levodopa/Carbidopa
- Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsCompletedPhase 2Bial - Portela C S.A.NCT01568047Written as Levodopa/Carbidopa
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.CompletedPhase 3Bial - Portela C S.A.NCT01227655Written as Carbidopa
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonCompletedPhase 3Bial - Portela C S.A.NCT01568073Written as Carbidopa
- A Study of MK0657 in Parkinson's Disease Patients (0657-006)CompletedPhase 1Merck Sharp & Dohme LLCNCT00505843Written as Comparator: carbidopa
- A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067CompletedPhase 2Bial - Portela C S.A.NCT01568034Written as Levodopa/Carbidopa
- An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's DiseaseCompletedPhase 2Intec Pharma Ltd.NCT00918177Written as Carbidopa/Levodopa, immediate release
Showing 20 of 21.
As the comparator · 5 — what is tested is compared with Carbidopa
- Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's DiseaseCompletedPhase 3AbbVieNCT04380142Written as Levodopa/Carbidopa (LD/CD)
- Pharmacokinetic Study in Healthy VolunteersCompletedPhase 1Orion Corporation, Orion PharmaNCT02554734Written as levodopa, carbidopa, entacapone
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy VolunteersCompletedPhase 1Orion Corporation, Orion PharmaNCT01840423Written as levodopa/carbidopa
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy VolunteersCompletedPhase 1Orion Corporation, Orion PharmaNCT01688089Written as Levodopa/carbidopa
- Stalevo in Early Wearing-Off PatientsCompletedPhase 4Orion Corporation, Orion PharmaNCT00125567Written as Levodopa/carbidopa
Codes
What other systems call Carbidopa · ClinicalTrials.gg INT007141
- MeSH (NLM) D002230CarbidopaConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) MNX7R8C5VOCARBIDOPA HYDRATEConfirmed FDA, NLM, Wikidata
- RxNorm 2019Confirmed FDA, Wikidata
- Wikidata Q414225(S)-(−)-carbidopa monohydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47431CarbidopaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D002230 | Carbidopa | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | MNX7R8C5VO | CARBIDOPA HYDRATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2019 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414225 | (S)-(−)-carbidopa monohydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47431 | Carbidopa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.